Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
In each of the two study arms (lapatinib plus topotecan or lapatinib plus capecitabine), the primary objective is to determine the CNS objective response rates in subjects with progressive brain metastases from ErbB2-overexpressing breast cancer. A CNS objective response is defined as either a Complete Response (CR) or Partial Response (PR), as assessed by volumetric analysis of brain magnetic resonance imaging (MRI), provided there is no progression of systemic disease outside of the CNS or increasing steroid requirements.
Critère d'inclusion
- Brain metastases from ErbB2-positive breast cancer